Registry of Lobbyists
| Corporation: | Eli Lilly Canada Inc. |
| Associated registration: | 954779-6034-35 |
| Communication date: | 2024-06-06 |
| Posted date: | 2024-07-15 |
| Designated Public Office Holders who participated in the communication: |
Daniel MacDonald,
Director General, Drugs for Rare Diseases
Strategic Policy Branch, Health Canada (HC) Michelle Boudreau, Executive Director Health Canada (HC) Bobby Chauhan, Director Health Canada (HC) |
| Subject Matter of the communication: | Health |
| Responsible Officer who filed this communication report: | Kenneth L Custer |
| As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed. | |